Table 1.
Clinicopathological characters of metastatic pancreatic cancer
| Group A | Group B | P value | |
|---|---|---|---|
| Gender (male/female) | 32/29 | 28/31 | 0.588 |
| Age (years) | 50.13±19.87 | 55.22±18.12 | 0.742 |
| Primary tumor location (head/other) | 31/30 | 32/27 | 0.711 |
| Previous Whipple procedure (yes/no) | 31/30 | 26/33 | 0.463 |
| Differentiation (well+moderate/poor) | 24/37 | 23/36 | 0.968 |
| Metastatic sites | |||
| Peritoneal lymph node | 30 | 27 | 0.711 |
| Liver | 37 | 39 | 0.540 |
| Lung | 27 | 32 | 0.278 |
| Number of Metastatic site | |||
| 1-3 | 34 | 30 | |
| > 3 | 27 | 29 | 0.595 |
| CEA (U/ml) | 8.61±7.16 | 9.12±8.33 | 0.482 |
| CA199 (U/ml) | 1215±997 | 1510±1120 | 0.347 |
| Performance status (median) | 1.0 | 2.0 | 0.472 |
| VAS (median) | 6.0 | 7.0 | 0.094 |
| S1 treatment (mean) | 4.35 | 3.88 | 0.554 |
VAS: visual analog scale.